Back to top

Image: Bigstock

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Read MoreHide Full Article

Key Takeaways

  • REGN wins FDA approval for Livsayis, the first and only siRNA therapy for generalized myasthenia gravis.
  • Livsayis is under EU review, with a European Commission decision expected in the second half of 2027.
  • Livsayis carries a Boxed Warning for serious meningococcal infections and requires a restricted REMS program.

Regeneron Pharmaceuticals (REGN - Free Report) announced that the FDA has approved Livsayis (cemdisiran) for treating adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, the predominant form of the disease.

Following the nod, Livsayis became the first and only siRNA therapy to be approved for gMG. It is also the only FDA-approved therapy for gMG administered subcutaneously four times a year.

The approval marks an important milestone for Regeneron, as Livsayis is the company's first approved siRNA therapy and its first approved medicine in neurology.

Livsayis is a novel C5-directed small interfering RNA (siRNA) therapy that lowers circulating C5 protein levels, thereby inhibiting terminal complement activation, which is a key driver of gMG.

Year to date, shares of Regeneron have rallied 22.9% compared with the industry’s increase of 6.8%.

Zacks Investment Research
Image Source: Zacks Investment Research

FDA Nod for REGN’s Livsayis Based on NIMBLE Study Data

The FDA approval for Livsayis was based on positive results from the phase III NIMBLE study, which demonstrated significant improvements in disease symptoms and muscle function following treatment with Livsayis compared with placebo.

At week 24, treatment with Livsayis demonstrated a 4.5-point improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score from baseline compared with a 2.2-point improvement with placebo. Additionally, 76.6% of patients treated with Livsayis achieved at least a 3-point improvement in MG-ADL scores compared with 44.1% in the placebo group.

Treatment with Livsayis demonstrated a rapid onset of clinically meaningful benefit, with improvements in MG-ADL scores observed as early as two weeks after treatment initiation. Disease control and symptom relief were sustained through 24 weeks, with no indication of waning efficacy.

However, the prescribing information for Livsayis includes a Boxed Warning for serious meningococcal infections, along with warnings and precautions for other serious infections.

Livsayis will be available through a restricted Risk Evaluation and Mitigation Strategy program, consistent with other FDA-approved medicines that reduce C5 activity.

More on REGN’s Livsayis Development

Livsayis is currently under review in the European Union for the treatment of adults with gMG. A decision from the European Commission is anticipated in the second half of 2027.

Regulatory filings for Livsayis are also planned in other geographies, including Japan.

Myasthenia gravis (MG) is a rare, chronic autoimmune disorder, wherein abnormal anti-AChR antibodies activate the complement system, including C5, disrupting communication between nerves and muscles that results in debilitating and potentially life-threatening muscle weakness.

Patients with gMG commonly experience extreme fatigue, as well as difficulties with facial movements, speech, swallowing and mobility.

Please note that Regeneron is solely responsible for the development, manufacturing, and commercialization of Livsayis through a worldwide licensing agreement with Alnylam (ALNY - Free Report)

Regeneron and ALNY have collaborated to discover, develop, and commercialize RNAi therapeutics for numerous diseases by addressing therapeutic disease targets expressed in the eye and central nervous system, in addition to a select number of targets expressed in the liver.

REGN’s Zacks Rank & Other Stocks to Consider

Regeneron currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the biotech sector are Vericel (VCEL - Free Report) and Eton Pharmaceuticals (ETON - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, estimates for Vericel’s 2026 earnings per share have risen from 54 cents to 78 cents, while estimates for 2027 have increased from 84 cents to 98 cents during the same time. VCEL shares have surged 62.9% year to date.

Vericel’s earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with the average surprise being 367.50%.

Over the past 30 days, estimates for Eton Pharmaceuticals’ 2026 earnings per share have risen from $1.13 to $1.54, while estimates for 2027 have increased from $1.94 to $2.36 during the same time. ETON shares have skyrocketed 266.6% year to date.

Eton Pharmaceuticals’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 80.40%.

Published in